Skip to main
XGN

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen Inc. has demonstrated significant growth potential, evidenced by a year-to-date share increase of 133%, marking it as a frontrunner in the diagnostics sector. The company reported a 19% year-over-year revenue growth for the first nine months, supported by a balanced 9% increase in average selling prices (ASPs) and an 8% rise in testing volumes. Additionally, Exagen’s Q3 performance reflected a remarkable 38% year-over-year revenue growth, bolstered by improvements in both volume and pricing, positioning the company favorably for future expansion within the market.

Bears say

Exagen Inc. has faced a negative outlook due to a significantly lowered growth forecast for 2026, alongside delays in achieving positive free cash flow. This revision is compounded by reduced revenue growth estimates and diminished expectations for average selling price (ASP) and gross margin expansion in the near term. Additionally, the company has shown a notable decline in its stock value, with shares dropping more than 60% following its third-quarter 2025 results, raising concerns among investors about growth prospects and profitability.

Exagen Inc (XGN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of Apr 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.